Bicycling and Mortality Among Individuals With diabetesNutrition (EPIC)
1 other identifier
observational
12,848
1 country
1
Brief Summary
The primary aim of the study is to study the relationship between overall bicycling and all-cause mortality and secondarily cardiovascular disease mortality among individuals with diabetes from European countries. A secondary aim will be to study the relation of change in bicycling to all-cause mortality and cardiovascular disease mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 15, 2019
CompletedStudy Start
First participant enrolled
November 20, 2019
CompletedFirst Posted
Study publicly available on registry
November 21, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2020
CompletedJanuary 2, 2020
December 1, 2019
5 months
November 15, 2019
December 29, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
All-cause Mortality
0 (Alive at follow-up) or 1 (Death at follow-up)
From 0 years and up to 17 years or until death from any cause, whichever comes first.
Secondary Outcomes (1)
Cause specific mortality: Cardiovascular
From 0 years and up to 17 years or until death from any cause, whichever comes first.
Other Outcomes (2)
Cause specific mortality: Cardiovascular
From 4-6 years (second examination) after 0 years (first examination) and up to 12 years or until death from any cause, whichever comes first.
All-cause Mortality
From 4-6 years (second examination) after 0 years (first examination) and up to 12 years or until death from any cause, whichever comes first.
Study Arms (1)
Patients with diabetes at the baseline assessement in EPIC
Self-reported and confirmed diabetes (validated by a second source (at least 1), including repeated self-report, contact with physician, linkage to register later point, intake of diabetes medicine, registration of diabetic chiropody, baseline glycated hemoglobin\>=6.0%, five annual blood glucose measurements or two blood glucose measurements per year for five consecutive years) cases were included in the analyses. No information is available to distinguish between type 1 and type 2 diabetes across the population but type 1 is rare by comparison.
Interventions
Total bicycling is reported in categories of: (0 - reference), (\>0 to \<60), (≤60 to \>150), (≤150 to \< 300) and (≥300) minutes/week
Eligibility Criteria
See Statistical Analysis Plan
You may qualify if:
- Confirmed or self-reported diabetes at first examination
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rigshospitalet, Denmarklead
- University of Southern Denmarkcollaborator
Study Sites (1)
Center for Physical Activity Research, Copenhagen University Hospital
Copenhagen, 2100, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mathias Ried-Larsen, PhD
Copenhagen University Hospital, Centre for Physical Activity Research
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 14 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Researcher
Study Record Dates
First Submitted
November 15, 2019
First Posted
November 21, 2019
Study Start
November 20, 2019
Primary Completion
April 30, 2020
Study Completion
April 30, 2020
Last Updated
January 2, 2020
Record last verified: 2019-12
Data Sharing
- IPD Sharing
- Will not share
Request for individual patient data should be directed to the International Agency for Research on Cancer (IARC) The predefined statistical analyses plan is available (see link)